Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Zacks
More News
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Zacks
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Zacks
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
Artisan Sold?Cencora?(COR) as Earnings Momentum Slowed...
Yahoo! Finance: News
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Zacks
Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus
Accelerant, Shopify and Carpenter Technology delivered strong gains, while Zacks upgrades and model portfolios spotlight key performers.
Zacks
Notable Two Hundred Day Moving Average Cross - COR
In trading on Thursday, shares of Cencora Inc (Symbol: COR) crossed below their 200 day moving average of $323.14, changing hands as low as $321.12 per share. Cencora Inc shares are currently trading off about 1.8% on the day. The chart below shows the one year performance of...
Nasdaq News: Markets
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Zacks
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.